Multiple myeloma is challenging to diagnose because its presentation is often nonspecific and overlaps with other conditions. Fatigue and skeletal pain can often be attributed to other conditions or simply just general aging. Definitive diagnosis requires specialized assessments. The following multiple myeloma guidelines represent some of the more recent options that better equip physicians with evidence-based recommendations from clinical societies.
The following guidelines focused on multiple myeloma come from the International Myeloma Working Group or the European Hematology Association and range in publication from 2022 through 2025.
- Sequencing Immunotherapy for Treatment of Multiple Myeloma
- International Myeloma Working Group, 2025
- Evidence-Based Guidelines for Diagnosis, Treatment and Follow-up of Patients with Multiple Myeloma
- European Hematology Association, 2025
- Optimal Use of T-Cell-Engaging Bispecific Antibodies in Multiple Myeloma
- International Myeloma Working Group, 2024
- Management and Response Assessment of Chimeric Antigen Receptor T-Cell Therapy in Clinical Practice for Relapsed and Refractory Multiple Myeloma
- International Myeloma Working Group, 2024
- Management of Multiple Myeloma-Related Renal Impairment
- International Myeloma Working Group, 2023
- Infection Prevention in Multiple Myeloma
- International Myeloma Working Group, 2022
Check out other clinical guidelines and sign up for alerts to stay informed on the latest published clinical guidelines and guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.